Royal Bank of Canada
SLRN

Royal Bank of Canada’s ACELYRIN SLRN Stock Holding History

Royal Bank of Canada’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,263
Closed -$13K – 7328
2025
Q1 		$13K Sell
5,263
-17,265
-77% -$41.1K ﹤0.01% 6074
2024
Q4 		$71K Buy
22,528
+14,028
+165% +$67.9K ﹤0.01% 5511
2024
Q3 		$42K Buy
8,500
+385
+5% +$1.99K ﹤0.01% 5792
2024
Q2 		$36K Buy
8,115
+4,512
+125% +$21.1K ﹤0.01% 5808
2024
Q1 		$24K Sell
3,603
-7,061
-66% -$53.6K ﹤0.01% 5846
2023
Q4 		$80K Buy
10,664
+5,716
+116% +$48.8K ﹤0.01% 5748
2023
Q3 		$50K Sell
4,948
-26,046
-84% -$553K ﹤0.01% 5785
2023
Q2 		$648K Buy
+30,994
New +$634K ﹤0.01% 3740

Other funds holding SLRN

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Royal Bank of Canada's SLRN Position: Q2 2025 in Review

Royal Bank of Canada sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 5,263 shares — an estimated $13K sold.

Royal Bank of Canada first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $648K in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

  • Royal Bank of Canada reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 5,263 ACELYRIN shares in Q2 2025, an estimated $13K.
  • Royal Bank of Canada first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
  • Royal Bank of Canada's ACELYRIN position peaked at $648K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.